Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.
暂无分享,去创建一个
Daniel J Sargent | Daniel G Haller | Marc Buyse | Paul J Catalano | Michael O'Connell | Norman Wolmark | Thierry Andre | David Kerr | R. Labianca | D. Kerr | D. Sargent | M. Buyse | P. Catalano | H. Wieand | N. Wolmark | R. Gray | R. Goldberg | A. Grothey | M. O’connell | D. Haller | C. O'Callaghan | J. Seitz | A. de Gramont | G. Francini | T. André | Roberto Labianca | J. Benedetti | Axel Grothey | Richard M Goldberg | Richard Gray | Jean Francois Seitz | C. Blanke | Charles D Blanke | Aimery De Gramont | Christopher J O'Callaghan | Guido Francini | Erin Green | Harry S Wieand | Jacqueline K Benedetti | E. Green
[1] G. Molenberghs,et al. The validation of surrogate endpoints in meta-analyses of randomized experiments. , 2000, Biostatistics.
[2] T R Fleming,et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. , 1990, The New England journal of medicine.
[3] A. Norman,et al. The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] H. Rockette,et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] B. Efron,et al. A Leisurely Look at the Bootstrap, the Jackknife, and , 1983 .
[6] H. Rockette,et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. , 1988, Journal of the National Cancer Institute.
[7] M. Kahn,et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. P. Pignon,et al. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators , 1995, The Lancet.
[9] D. Sargent,et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Marc Buyse,et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Paul S Albert,et al. Assessing surrogates as trial endpoints using mixed models , 2005, Statistics in medicine.
[12] David R. Cox,et al. Regression models and life tables (with discussion , 1972 .
[13] T. Fleming,et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] T. Hickish,et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.
[15] B. Graubard,et al. Statistical validation of intermediate endpoints for chronic diseases. , 1992, Statistics in medicine.
[16] C. Begg,et al. On the use of surrogate end points in randomized trials , 2000 .
[17] J. Bryant,et al. Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05. , 1998, Journal of the National Cancer Institute.
[18] Daniel J Sargent,et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] H. Rockette,et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] H. Wieand,et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] G. Molenberghs,et al. Validation of surrogate end points in multiple randomized clinical trials with failure time end points , 2001 .
[22] A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. , 2001, The New England journal of medicine.
[23] S. Cha,et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Marco Lorenzi,et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. , 1994, Gastroenterology.
[25] L. Saltz,et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.
[26] D. Kerr,et al. QUASAR: A randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] D. DeMets,et al. Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.
[28] R. Prentice. Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.
[29] M. Somerfield,et al. 2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] M. Somerfield,et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] D. Kerr,et al. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial , 2000, The Lancet.
[32] H. Rockette,et al. Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.